ENQUIRE NOW

Blog

Blog

Common Sources of Extractables and Leachables in Pharmaceutical Packaging Systems
09
Apr
By No Comments

Common Sources of Extractables and Leachables in Pharmaceutical Packaging Systems

Pharmaceutical packaging does more than contain a product. It directly influences product protection, shelf life, and contamination risk. Packaging materials are designed to preserve formulation quality, support stability, and protect the product throughout storage and use. But they can also introduce chemical risk. Materials used in containers, closures, liners, tubing, seals, and other packaging-associated components […]
Continue Reading
Q1, Q2, and Q3 Studies Explained: A Step-by-Step Guide for Formulators
30
Mar
By No Comments

Q1, Q2, and Q3 Studies Explained: A Step-by-Step Guide for Formulators

When developing topical and transdermal generic drug products, overlooking Q1, Q2, and Q3 alignment early in development can result in regulatory deficiency letters, repeat IVPT studies, or the need for costly clinical endpoint trials. This is why Q1/Q2/Q3 strategies are foundational. These classification tiers, Q1 (Qualitative Sameness), Q2 (Quantitative Sameness), and Q3 (Structural and Physicochemical […]
Continue Reading
The Role of Franz Diffusion Cell in IVRT and IVPT Studies
27
Mar
By No Comments

The Role of Franz Diffusion Cell in IVRT and IVPT Studies

The Franz diffusion cell system remains the gold-standard analytical platform for evaluating drug release and skin permeation in topical product development. Whether for in vitro release testing (IVRT) across synthetic membranes or in vitro permeation testing (IVPT) across biological skin, Franz diffusion systems form the backbone of regulatory-grade topical bioequivalence programs. At Topiox Research, Franz […]
Continue Reading
Why Early Formulation Optimization Saves Time and Cost
13
Feb
By No Comments

Why Early Formulation Optimization Saves Time and Cost

In topical and transdermal product development, time and cost are the biggest constraints, and poor formulation design is often the hidden cause of both. Across the pharmaceutical industry, late-stage reformulation is among the most expensive mistakes R&D teams make. Each adjustment to the composition, process, or stability profile triggers new analytical, IVRT/IVPT, and bioequivalence studies, […]
Continue Reading
Challenges in Topical Drug Product Development and How to Solve Them
09
Feb
By No Comments

Challenges in Topical Drug Product Development and How to Solve Them

Developing a successful topical formulation isn’t a simple mix-and-match of ingredients.It’s a fine balance of science, structure, and stability where one overlooked factor can cause failure in bioequivalence, stability, or regulatory review. At Topiox Research Centre, our formulation scientists in Navi Mumbai help pharmaceutical and cosmetic brands solve these challenges with data-driven, regulatory-ready solutions. This […]
Continue Reading